Inês Mota Postdoctoral Associate in Radiation Oncology

Postdoctoral Associate in Radiation Oncology, Radiation Oncology , Weill Cornell Medical College 2021 -
Fellow in Radiation Oncology, Radiation Oncology , Weill Cornell Medical College 2021 - 2021

Publications

Sort by

Co-Author Network

Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load. Cell reports. 2024 Academic Article GET IT
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer cell. 2023 Academic Article GET IT
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nature cancer. 2023 Academic Article GET IT
Times cited: 18
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. Science translational medicine. 2023 Academic Article GET IT
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2022 Academic Article GET IT
Times cited: 23
Comment on "ALK is a therapeutic target for lethal sepsis". Science translational medicine. 2018 Comment GET IT
Times cited: 7
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nature medicine. 2018 Academic Article GET IT
Times cited: 52
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers. 2018 Review GET IT
Times cited: 82

Sort by

Co-investigator Network

Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory awarded by United States Department of Defense Key Personnel 2021 - 2025
Converting HR Breast Cancer Into an Individualized Vaccine awarded by United States Department of Defense Key Personnel 2019 - 2025
Converting HR+ Breast Cancer Into an Individualized Vaccine awarded by United States Department of Defense Key Personnel 2019 - 2025